Showing posts with label Siemens Healthineers. Show all posts
Showing posts with label Siemens Healthineers. Show all posts

Saturday, February 19, 2022

The Siemens Healthineers Is Looking Better And Better

 

Siemens Healthineers (OTCPK:SMMNY) is one of those frustrating situations for a GARP investor where you have to make your peace with paying more than you'd really like to own a piece of a business that I think is set up to be one of the best large-cap med-techs over the next three to five years. Best-of-breed R&D is driving share gains in imaging, diagnostics is improving, and Varian is a top-tier addition in the radiation oncology space.

Valuation is still an issue for me. The shares have pulled back significantly off their high, but are up about 10% from my last article and still don't offer huge undervaluation. This is a case, though, where I think investors may want to consider paying up for quality and the opportunity to enjoy upside leverage to beat-and-raise quarters down the line.


Read more here: 

The Siemens Healthineers Is Looking Better And Better

Saturday, April 10, 2021

Siemens Healthineers Offers More Than Just Acquired Growth And Synergy Opportunities

 

The market’s mood has certainly improved where Siemens Healthineers (OTCPK:SMMNY) (OTC:SEMHF) is concerned. Whether that’s due to a strong fiscal first quarter result that showed a good recovery in imaging, the fact that the Varian (VAR) financing is complete and on better-than-expected terms, or just improving sentiment, I don’t think shareholders are going to look that particular gift horse in the mouth.

Healthineers has done better than I’d expected in the relatively short time since my last update. Up about 25%, Healthineers has been outperformed very slightly by Philips (PHG) (on which I’ve been bullish), but has outperformed other med-techs like Abbott (ABT) and Intuitive Surgical (ISRG). Keep in mind, though, that the shares underperformed after the Varian announcement, so on a one-year comparison, Healthineers is still the laggard of that group (though still up more than 35%).

I still like Siemens Healthineers as a business, and I think the acquisition of Varian will ultimately be looked at as a good move. I’m also bullish on some of the company’s own organic growth initiatives, including new offerings in imaging and diagnostics. Valuation isn’t great right now, but it’s not much worse than other quality med-techs, and I can see a sound argument for holding, particularly with an improving capital equipment environment and possible upside from COVID-19 antigen testing.

 

Read more here: 

Siemens Healthineers Offers More Than Just Acquired Growth And Synergy Opportunities

Tuesday, September 22, 2020

Siemens Healthineers Expanding The Business, But Self-Help Is Still Needed

Since its spin-out from Siemens (OTCPK:SIEGY) in the spring of 2018, Siemens Healthineers (OTCPK:SMMNY) has had a rather lackluster run – underperforming the med-tech space by over 20% before the announced acquisition of Varian (VAR) opened the gap even further. While Siemens Healthineers has a market-leading, and quite profitable, imaging business, investors have been disappointed by the lack of progress in the diagnostics business, and it seems fair to assume that with the need to integrate Varian and do whatever is necessary to ensure the success of that large deal, diagnostics may not get the TLC it needs for a while longer.

With the shares underperforming more significantly since the early August announcement of the Varian deal, a lot of premium has been wrung out of Siemens Healthineers shares. It’s still not significantly undervalued, but I can see the possibility of a mid-to-high single-digit annualized return from this level, and if management can deal more effectively with the issues in the diagnostics business, there could be additional upside.

Click here to continue: 

Siemens Healthineers Expanding The Business, But Self-Help Is Still Needed